Log In

New? Register Here

ZIOPHARM Oncology Inc.

1180 Avenue of the Americas. Suite 2020
NEW YORK, NY 10036

  • Main Phone: (646) 214-0700
  • Fax Number: (646) 214-0711
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Endorsements: None Provided
  • Announcements: 0


ZIOPHARM Oncology, Inc. (ZIOPHARM) is a biopharmaceutical company that focuses on the discovery and development of new cancer therapies. ZIOPHARM is applying its technologies in cancer research to develop therapeutics for patients. The Company s portfolio consists of five clinical-stage product candidates, as well as multiple research-stage candidates. ZIOPHARM s clinical programs include palifosfamide (ZIO-201), IL-12 DNA, indibulin (ZIO-301) and darinaparsin (ZIO-101). Palifosfamide (ZIO-201) is a deoxyribonucleic acid (DNA)-targeted cancer treatment that bypasses drug resistance mediated by aldehyde dehydrogenase (ALDH), an enzyme associated with cancer stem cells, and has a favorable toxicity profile. IL-12 DNA is a DNA therapeutic that is delivered to the patient's tumor and expresses interleukin-12, a protein that controls anti-cancer immune responses.


Not provided at this time


Not provided at this time


There are no company announcements at this time.

Company's Strengths and Specialties

There is no information provided at this time.